Beyond triple agonism: many receptors, one engineered peptide.
A classical drug aims at one receptor and hopes the rest of the body does not notice. A new generation of peptide medicines broke that rule on purpose: tirzepatide engages two receptors, retatrutide three. Panacea Bio Chem's Multiagonist programme asks the design question at its limit: what would it take for one amino acid chain to engage many at once?
Agonism, from the ground up
Receptors are the cell's antennas — proteins that read chemical signals and convert them into action. The vocabulary of modern pharmacology begins with two words.
Agonist — the switch-on
An agonist binds a receptor and activates it, standing in for the body's own signal. Insulin, adrenaline and GLP-1 all act through receptors; the medicines built on them are agonists.
Antagonist — the blockade
An antagonist occupies the same docking site but flips nothing: it physically prevents the natural signal from getting through. Beta-blockers and antihistamines are everyday examples.
Selectivity — the classic bargain
For a century the art of drug design was narrowing: one molecule, one receptor, minimal cross-talk. Fewer targets meant fewer surprises — and, often, less reach than a disease demands.
Polyagonism — the deliberate opposite
Metabolic and neurological diseases are network problems. Morphy and Rankovic formalised the counter-strategy in 2005: design one ligand to engage several receptors on purpose — a "designed multiple ligand" (J. Med. Chem. 2005).
What we show, and what we hold back
This page presents a research direction, not a product. The named medicines above belong to their makers, whose published trials we cite and credit; Panacea's own programme is disclosed at concept level.
Shown
The pharmacology of agonism, the credited history of multi-receptor ligands, the public trial record of dual and triple agonists, and the design reasoning behind pursuing many at once.
Held back
The programme's target receptors, sequences, folding routes and assay results. A programme of this kind earns its claims in the literature, not on a webpage — disclosure follows data.
Counting receptors: the numbered era
The peptide field now counts receptors the way the space race counted engines — and every number so far has been earned in public.
Two — tirzepatide (GIP + GLP-1)
- Eli Lilly's tirzepatide is a single peptide engineered to activate both the GIP and GLP-1 receptors — the "twincretin".
- SURPASS-2 (Frías et al., NEJM 2021): superior glucose control to semaglutide in type 2 diabetes (trial record).
- SURMOUNT-1 (Jastreboff et al., NEJM 2022): up to ~20.9% mean body-weight reduction over 72 weeks (trial record). Approved by the FDA as Mounjaro (2022) and Zepbound (2023).
Three — retatrutide (GIP + GLP-1 + glucagon)
- Retatrutide adds the glucagon receptor — one peptide, three metabolic receptors. Phase 2 (Jastreboff et al., NEJM 2023): up to ~24.2% mean weight reduction at 48 weeks (trial record).
- Phase 3 TRIUMPH-4 (Lilly, December 2025): ~28.7% mean weight loss at 68 weeks, the first successful phase 3 for a triple agonist (Lilly announcement).
- Matthias Tschöp and Richard DiMarchi call this "unimolecular polypharmacology" — one molecule reading a multi-receptor chord (Nat. Rev. Drug Discov. 2022).
What the numbers in these names actually mean
In this series the number names the count of receptor arms a design aims at. It is a design target, not a claim that an approved medicine with that many arms exists.
Penta is five, hexa six, septa seven, octa eight, nona nine, deca ten. A domain or a programme carrying one of those prefixes is telling you what constellation of receptors its design is written against — nothing more and nothing less. Read that way, the whole series becomes legible: the numbers describe ambition and architecture, and the evidence stage of each rung is a separate question, answered in the table below.
This is the interpretive key for every count-named page in the family, and it is kept here. Where another page in the series states a number, it means this.
Which rungs are real? — the evidence stage, rung by rung
The field publishes effect sizes and leaves the reader to guess how mature each rung is. This table publishes the maturity instead. Registry records were re-fetched from the ClinicalTrials.gov API on 5–6 September 2026 and reflect what the registry held then.
| Rung | Representative molecule | Highest stage reached | Registry position |
|---|---|---|---|
| One | Semaglutide (GLP-1) | Approved medicine | Phase-3 obesity result published in the peer-reviewed literature |
| Two | Tirzepatide (GIP + GLP-1) | Approved medicine | Phase-3 results published; head-to-head against semaglutide published |
| Three | Retatrutide (GIP + GLP-1 + glucagon) | — not approved anywhere | Phase 2 NCT04881760 completed with results posted. Phase 3: TRIUMPH-1 (n=2,335), TRIUMPH-2 (n=1,152), TRIUMPH-3 (n=1,946) and TRIUMPH-4 (n=445) all completed, none with results posted to the registry. Pre-approval expanded access is open under NCT07629401 |
| Three vs two | Retatrutide against tirzepatide | Running | TRIUMPH-5, phase 3, n=800, active and no longer recruiting, completion listed December 2026 — the first head-to-head that tests one rung directly against another |
| Four and above | — | No qualifying example identified in our search | In our dated search of ClinicalTrials.gov and the scientific literature on 5 September 2026 we identified no clinically registered or published unimolecular agonist targeting more than three distinct receptor systems. One external candidate, NA-931 (Biomed Industries), is described by its sponsor as a four-target agonist and challenges that finding; its qualification is unresolved because sources conflict on its molecular class. Patent claim text, the EU CTIS and ISRCTN registers, the China CDE register and non-English literature were not searched. The full map is at decagonist.com |
| Panacea's own series | The count-named programmes | Design stage | Presented on this site as design-stage work. No molecule, binding data or clinical result is claimed here |
A distinction this table exists to protect. A completed trial is not a published result, and a company announcement is not a registry-posted one. The ~28.7% figure circulating for TRIUMPH-4 is a company topline: the trial is registry-confirmed as completed, the registry holds no posted results for it, and the percentage comes from the sponsor. Where the same trial is reported elsewhere as ~30%, that is rounding in secondary coverage rather than a second finding — which is exactly why the number should always travel with the source that produced it.
Does adding receptors keep working?
It is the honest question to ask of a family whose names are counts, and the honest answer is that there is no formula in which more receptors means more benefit. What the literature supports is narrower and more interesting: benefit comes from complementarity — arms whose effects add and whose weaknesses cancel — and from the balance struck between them, not from the count itself. Two molecules engaging exactly the same three receptors need not behave alike, because the relative potency at each arm is what distinguishes them.
Three limits sit alongside that, and they are separate axes rather than one:
- Tolerability, not efficacy, sets the ceiling. Gastrointestinal tolerability is what caps the dose of every agent in this class, so an arm that deepens satiety may also lower the dose a person can reach.
- Durability is its own question. How much of an effect persists, and what happens after stopping, is not answered by how many receptors were engaged.
- Nothing above three has been tested in a person. The rung table above is the current state of that, dated.
Which is why this series is presented as a design programme about which voices belong in one chord, rather than as an argument that more voices are better.
Where each part of this subject is answered
One question, one home. This page owns agonism as a concept, the credited history and the naming key above; the rest of the subject is answered by the page that owns it.
The ladder, rung by rung
The full multi-agonist ladder and the dated frontier map: decagonist.com.
How a triple agonist works
One chain, three locks — the mechanism in detail: triagon.co.uk. The programme and its synthesis: triagon.uk.
The GLP-1 root
The incretin effect, what GLP-1 does, and how a two-minute hormone became a weekly medicine: panaglutide.com.
The class record
Incretin multi-agonism as a class, and why two triagonists are not the same drug: decarutide.com.
The glucagon arm
Energy expenditure as the fuel-burning half of the balance: panatrutide.com.
The fourth arm, and the fifth
Which arm should come next: quadagonist.com. The penta rung: pentatrutide.com. The amylin arm: amylcaltrutide.com.
The Multiagonist programme
At Panacea Bio Chem, Bogdan Dicoias runs an amino acid chain (AAC) design practice: sequences are engineered residue by residue, folded, and profiled against receptor panels. The Multiagonist series takes that practice to the number the field has not attempted: many receptors engaged by one engineered peptide — not as several drugs in a cocktail, but as one chain whose surface is tuned, position by position, to a chosen multi-receptor constellation.
Honesty boundary: this is a design-stage research programme. We publish the concept, the public science it stands on, and the design philosophy — we do not claim a finished molecule, binding data, or any clinical result here. The specific receptor constellation and sequence work remain Panacea intellectual property while the programme matures.
Illustrative programme disclosure · no results are claimed on this page
"The field counted one, then two, then three — and each step looked excessive until it worked. We do not assume the counting stops at three. An amino acid chain has enough addressable surface to speak to more than one receptor; the craft is choosing which voices belong in one chord, and tuning every residue so the chord holds."
Bogdan Dicoias — Biochemist · AAC Designer · Panacea Bio Chem Ltd
Frequently asked questions
What is a receptor agonist?
A molecule that binds a receptor and switches it on, mimicking the body's own signal. An antagonist binds the same site and blocks the signal instead.
What is a multi-receptor agonist?
One molecule engineered to activate several receptors at once — a designed multiple ligand. Tirzepatide (two) and retatrutide (three) are the clinical landmarks.
Does an eight-receptor agonist exist as a medicine?
No. The clinical frontier today is triple agonism, and no approved medicine engages more receptors than that by design. The evidence stage of every rung, with its registry records and the date they were checked, is in Which rungs are real? above. Panacea's Multiagonist series is a design-stage programme, presented as such.
What do the numbers in these names mean?
The number names the count of receptor arms a design aims at — penta five, hexa six, septa seven, octa eight, nona nine, deca ten. It is a design target, not a claim that an approved medicine with that many arms exists. The full key is at What the numbers in these names actually mean.
Does adding more receptors keep working?
There is no formula in which more receptors means more benefit. Complementarity and balance between the arms drive benefit, not the count — and tolerability, not efficacy, is what caps the dose of every agent in this class. See Does adding receptors keep working?
Who pioneered multi-agonist peptides?
Morphy and Rankovic formalised designed multiple ligands in 2005; Tschöp and DiMarchi advanced unimolecular polypharmacology; Eli Lilly brought tirzepatide and retatrutide to the clinic. The credited timeline is on The Research. More on the Questions page.
Trending in the field
Recent developments in the field — refreshed 2026-10-22 by Panacea Bio Chem.
- Dose-Response Profiles in Incretin and Multi-Agonist Obesity Pharmacotherapy — PubMed, 2026 Oct 20
- The development of obesity pharmacotherapy: from early challenges and setbacks to recognition by WHO — PubMed, 2026 Oct 19
- Glucagon-Like Peptide-1 Receptor Agonist and Gastrointestinal Adverse Effects: A Comprehensive Review — PubMed, 2026 Jul-Sep
- Interindividual variability in platelet aggregation among aspirin-treated patients: a large retrospective analysis — PubMed, 2026 Nov
